Merck Animal Health Announces Availability of CIRCUMVENT® CML Vaccine

Novel single-dose injectable vaccine delivers efficacy against three important swine diseases in one bottle

RAHWAY, N.J., June 7, 2023 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that CIRCUMVENT® CML vaccine is commercially available as part of its swine product portfolio. The company received license approval for the vaccine in the U.S. from the Department of Agriculture (USDA) in 2022.

CIRCUMVENT CML is the first ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, three weeks of age or older. With CIRCUMVENT CML, veterinarians and producers have the convenience of vaccinating for three of the most important swine disease concerns, all in one bottle with no mixing or reconstituting. 

“This vaccine complements the existing CIRCUMVENT PCV G2, PCV-M G2 and PORCILIS Ileitis product portfolio, providing swine veterinarians and producers with the additional option of vaccinating against disease caused by PCV2, Mycoplasma hyopneumoniae and Lawsonia intracellularis all in one bottle,” said Jamie Lehman, D.V.M., swine technical services veterinarian, Merck Animal Health. “Merck Animal Health continues to shape the future of animal health and well-being through the approval of CIRCUMVENT CML vaccine, which is our latest example of pioneering science that will help the industry improve both animal health and labor efficiency.” 

CIRCUMVENT CML is available in 100- and 500-ml vials. To learn more about our portfolio of swine health products and vaccines, visit www.DrivenByPrevention.com

CIRCUMVENT CML PRODUCT LABEL https://cvpln.com/mrk/nzsdj4X4 

Download the CIRCUMVENT CML Media Kit.

Merck Animal Health introduces CIRCUMBENT® CML, the first ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, three weeks of age or older. It is available in 100- and 500-ml vials.

About Merck Animal Health 

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of HealthierAnimals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.